selectION Secures $5M Promissory Note to advance its Kv1.3-selective peptide blocker into clinical development

BY      |     September 30, 2020

selectION, a biotechnology company developing novel peptide therapies for autoimmune diseases, announced a $5 million convertible promissory note financing. The funds will be used to advance selectION’s lead candidate, si-544, into clinical development in early 2021.

si-544 is the best-in-class Kv1.3-selective peptide blocker for the treatment of effector memory T cell-driven diseases, like autoimmune diseases (Vasculitis, Rheumatoid Arthritis or Multiple Sclerosis) or certain rare cancers (like cutaneous T cell lymphoma). si-544 selectively binds to Kv1.3 with a picomolar IC50 and does not bind to other key functional ion channels, such as hERG or Kv1.5, avoiding off-target effects.

Preclinical safety and toxicology studies in rats and non-human primates showed a favorable safety profile. Importantly, the general immune response in rats was not impaired under si-544 therapy.

Read the press release here.

Read more about selectION here.

Image by Arek Socha from Pixabay

Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at
Alternatively, you can leave your comments on LinkedIn or Twitter.